Skip to main content

Table 2 Association of the TyG index with the absolute change, change rate and slope of baPWV

From: Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population

  model 1 model 2 model 3
β 95% CI P value β 95% CI P value β 95% CI P value
Change of baPWV (cm/s)
 TyG (continuous) 32.034 4.642–59.425 0.022 57.119 22.835–91.402 0.001 149.582 90.823–208.342 < 0.001
 Quartile 2 (ref: quartile 1) 59.745 10.509–108.982 0.017 61.086 12.582–109.59 0.014 76.297 28.63–123.964 0.002
 Quartile 3 85.613 36.416–134.81 0.001 93.631 43.889–143.373 < 0.001 102.562 52.08–153.044 < 0.001
 Quartile 4 74.957 25.494–124.42 0.003 98.555 37.584–159.526 0.002 129.525 58.723–200.326 < 0.001
 P for trend    0.002    < 0.001    < 0.001
Change rate of baPWV (cm/s/year)
 TyG (continuous) 11.892 3.415–20.368 0.006 17.974 7.307–28.642 0.001 40.372 21.853–58.891 < 0.001
 Quartile 2 (ref: quartile 1) 11.870 -3.385–27.125 0.127 12.122 -2.986–27.229 0.116 16.529 1.507–31.551 0.031
 Quartile 3 20.615 5.373–35.858 0.008 22.642 7.149–38.135 0.004 24.390 8.481–40.299 0.003
 Quartile 4 24.616 9.291–39.941 0.002 30.750 11.76–49.741 0.002 37.607 15.294–59.919 0.001
 P for trend    0.001    0.001    < 0.001
Slope of baPWV
 TyG (continuous) 9.570 1.538–17.601 0.020 14.238 4.121–24.355 0.006 34.874 17.238–52.51 < 0.001
 Quartile 2 (ref: quartile 1) 10.986 -3.469–25.441 0.136 10.888 -3.439–25.215 0.137 14.872 0.57–29.175 0.042
 Quartile 3 18.739 4.296–33.182 0.011 20.092 5.399–34.785 0.007 22.163 7.016–37.31 0.004
 Quartile 4 20.126 5.604–34.647 0.007 23.648 5.639–41.658 0.010 30.576 9.332–51.82 0.005
 P for trend    0.004    0.003    0.002
  1. Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up